Biopharma Funding Deals Halved from August to September 2024 Amid Diverse Pipeline Advances
CGeneTech
Small Molecule Innovative Drug Developer
LongBio
Next-Generation Large Molecule Antibody Developer
Hygieia
Small Interfering RNA (siRNA) Drug Developer
JHM Biopharma
Developer of Innovative Biotech Drugs
In 2024August, China's biopharmaceutical industry has shown extraordinary activity in the capital market,A Total of 14 Biopharmaceutical Enterprises Successfully Completed Financing This Month. This figure reflects investors' high recognition of the innovative potential in this field and their confidence in future development. However, enteringSeptember, financing activities have decreased somewhat,Only Seven Biopharmaceutical Enterprises Completed FinancingNevertheless, these enterprises cover multiple key areas in the industry, including gene editing, small molecule drugs, antibody drugs, small nucleic acid drugs, innovative drugs for membrane proteins, innovative drugs in the endocrine and metabolic fields, as well as the research and development of improved new drugs.
Biopharmaceutical Financing in China in August
(Image source: CDMO News)
Biomedical Financing in China for September
(Image source: Cytiva News)
Among these companies, Base Therapeutics stands out with itsGene Editing TherapyFields of focus, this technology has tremendous potential in the future of medical treatment. CGeneTech, on the other hand, is dedicated toSmall Molecule DrugsThe development of this class of drugs has shown significant effects in the treatment of various diseases. LongBio is committed toAntibody DrugsThe development of antibody drugs has been highly valued due to their precise therapeutic targets and fewer side effects. Hygieia Bio focuses onSmall Nucleic Acid DrugsThe research and development, which is an emerging field, is expected to provide new solutions for the treatment of genetic diseases.
Crystal Egg Biotech isMembrane Protein Innovative DrugDeep cultivation in the field, membrane proteins play a key role in drug development. Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. focuses onEndocrinology and MetabolismInnovative drug development in the field, which is of great significance for addressing the growing population of patients with metabolic diseases. Finally, Huiyong Pharmaceutical Research is committed toModified New DrugThe research and development, by improving the characteristics of existing drugs to enhance efficacy and reduce side effects.
Overall, although the number of financings in September 2024 decreased, the companies that completed financing have made arrangements in multiple key areas of the biopharmaceutical industry. The development of these companies will have a profound impact on the medical and health industry in China and even globally.
1. CaiLeiYing Pharma News
2. The rest of the materials are sourced from official media/online news.
Click "Pharmacology" below to follow more exciting content.
Disclaimer
The push rules of WeChat Official Accounts have changed again! If you don't click "Like" or set it as "Starred," we might get lost in the vast sea of articles~ Click here, don't miss out on the latest news from PharmaDJ! ??